Made in Colombia

News Releases

PharmaCielo Ltd. Appoints Anthony Wile as CEO

TORONTO, Canada (March 28, 2018) – The Board of Directors of PharmaCielo Ltd. (PharmaCielo) announced today the appointment of Anthony Wile as CEO, effective immediately. The Board of Directors also announced that Dr. Patricio Stocker has resigned from his operating position as President and CEO, and will assume a role on the Colombian Board of Directors.

“The Board of Directors and I are pleased that Mr. Wile has agreed to use his business leadership experience and knowledge to guide the next phase of the company’s operational development and growth. Working together with Federico Cock-Correa, CEO of PharmaCielo Colombia Holdings, we are confident that our operations are equipped for global growth and success,” said Simon Langelier, Chair. “Dr. Stocker must be thanked for his guidance through the first phase of the company’s life cycle and development of the infrastructure for the manufacture of cannabis oil extracts in Colombia.”

Dr. Stocker will continue to contribute to the next phase of the company’s growth and expansion providing leadership as a member of the Board of Directors of the Colombian operation.

“PharmaCielo has come a long way in a relatively short period of time. Now that the infrastructure is substantially in place and cultivation has begun, PharmaCielo is well positioned to ramp up production to meet global demand,” stated Mr. Wile. “I am looking forward to guiding the company in this process as well as establishing the organizational structure required to further build out PharmaCielo’s global operations.”

Mr. Wile is the co-founder of PharmaCielo and has been involved in its operations since the company was established. An entrepreneur, business strategist, publisher and author, Mr. Wile began his career in the Canadian investment industry with Scotia McLeod and Nesbitt Burns. 

Prior to founding PharmaCielo, Mr. Wile acted as a private equity investor and supported the launch and growth of enterprises in a number of global markets, including Colombia. Mr. Wile has lived and worked in several financial centres around the world, developing a network of leading international business and finance professionals.

Mr. Wile has also published a number of books focused on building private equity businesses and leveraging burgeoning investment trends to generate wealth.  A resident of Toronto, Canada and Medellin, Colombia, Mr. Wile graduated from Saint Mary’s University with a Bachelor of Commerce.

About PharmaCielo

PharmaCielo Ltd. is a global company privately held and headquartered in Canada with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors of standardized medical cannabis products. 

The boards of directors and executive teams of PharmaCielo Ltd. and PharmaCielo Colombia are comprised of a diversely talented group of international business executives and specialists with the relevant expertise to ensure long-term success. The team recognized the significant role Colombia’s ideal location would play in building a sustainable business in the medical cannabis industry and has built a strong business plan focused on supplying the international medical marketplace.

PharmaCielo Colombia Holdings S.A.S., a wholly owned subsidiary of PharmaCielo Ltd., is headquartered at the Company’s Nursery and Propagation Center based in Rionegro, Colombia.

 

This press release may contain forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or “recurring” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company’s products, currency exchange changes and risks, internal funding and the financial condition of the Company, product roll-out, competition, technological changes, and other commercial matters involving the Company, its products, and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. 

Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.